VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment

VolitionRx (VNRX) announces preprint availability of a new manuscript entitled “Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy.” This paper showcases both a new method, Capture-Seq, and new biomarkers for the detection of cancer. Volition has achieved 180-fold enrichment through its focus on chromosome fragments. Dr Jake Micallef, Chief Scientific Officer, Volition commented: “This is, I believe, a world-first breakthrough – it is the first time that transcription factor-bound DNA has been physically separated from the massive amounts of background DNA in the blood, and could, in my opinion, represent the biggest scientific breakthrough in cancer testing in recent years.”